Susan H Busch1, David A Fiellin1,2, Marek C Chawarski3, Patricia H Owens4, Michael V Pantalon4, Kathryn Hawk4, Steven L Bernstein4,5, Patrick G O'Connor2, Gail D'Onofrio4. 1. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA. 2. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 3. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. 4. Department of Emergency Medicine, Yale School of Medicine, New Haven, CT, USA. 5. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND AND AIMS: In a recent randomized trial, patients with opioid dependence receiving brief intervention, emergency department (ED)-initiatedbuprenorphine and ongoing follow-up in primary care with buprenorphine (buprenorphine) were twice as likely to be engaged in addiction treatment compared with referral to community-based treatment (referral) or brief intervention and referral (brief intervention). Our aim was to evaluate the relative cost-effectiveness of these three methods of intervening on opioid dependence in the ED. DESIGN: Measured health-care use was converted to dollar values. We considered a health-care system perspective and constructed cost-effectiveness acceptability curves that indicate the probability each treatment is cost-effective under different thresholds of willingness-to-pay for outcomes studied. SETTING: An urban ED in the United States. PARTICIPANTS: Opioid-dependent patients aged 18 years or older. MEASUREMENTS: Self-reported 30-day assessment data were used to construct cost-effectiveness acceptability curves for patient engagement in formal addiction treatment at 30 days and the number of days illicit opioid-free in the past week. FINDINGS: Considering only health-care system costs, cost-effectiveness acceptability curves indicate that at all positive willingness-to-pay values, ED-initiated buprenorphine treatment was more cost-effective than brief intervention or referral. For example, at a willingness-to-pay threshold of $1000 for 30-day treatment engagement, we are 79% certain ED-initiated buprenorphine is most cost-effective compared with other studied treatments. Similar results were found for days illicit opioid-free in the past week. Results were robust to secondary analyses that included patients with missing cost data, included crime and patient time costs in the numerator, and to changes in unit price estimates. CONCLUSION: In the United States, emergency department-initiated buprenorphine intervention for patients with opioid dependence provides high value compared with referral to community-based treatment or combined brief intervention and referral.
RCT Entities:
BACKGROUND AND AIMS: In a recent randomized trial, patients with opioid dependence receiving brief intervention, emergency department (ED)-initiated buprenorphine and ongoing follow-up in primary care with buprenorphine (buprenorphine) were twice as likely to be engaged in addiction treatment compared with referral to community-based treatment (referral) or brief intervention and referral (brief intervention). Our aim was to evaluate the relative cost-effectiveness of these three methods of intervening on opioid dependence in the ED. DESIGN: Measured health-care use was converted to dollar values. We considered a health-care system perspective and constructed cost-effectiveness acceptability curves that indicate the probability each treatment is cost-effective under different thresholds of willingness-to-pay for outcomes studied. SETTING: An urban ED in the United States. PARTICIPANTS: Opioid-dependent patients aged 18 years or older. MEASUREMENTS: Self-reported 30-day assessment data were used to construct cost-effectiveness acceptability curves for patient engagement in formal addiction treatment at 30 days and the number of days illicit opioid-free in the past week. FINDINGS: Considering only health-care system costs, cost-effectiveness acceptability curves indicate that at all positive willingness-to-pay values, ED-initiated buprenorphine treatment was more cost-effective than brief intervention or referral. For example, at a willingness-to-pay threshold of $1000 for 30-day treatment engagement, we are 79% certain ED-initiated buprenorphine is most cost-effective compared with other studied treatments. Similar results were found for days illicit opioid-free in the past week. Results were robust to secondary analyses that included patients with missing cost data, included crime and patient time costs in the numerator, and to changes in unit price estimates. CONCLUSION: In the United States, emergency department-initiated buprenorphine intervention for patients with opioid dependence provides high value compared with referral to community-based treatment or combined brief intervention and referral.
Authors: Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed Journal: Value Health Date: 2005 Sep-Oct Impact factor: 5.725
Authors: Daniel Polsky; Henry A Glick; Jianing Yang; Geetha A Subramaniam; Sabrina A Poole; George E Woody Journal: Addiction Date: 2010-07-12 Impact factor: 6.526
Authors: Gail D'Onofrio; David A Fiellin; Michael V Pantalon; Marek C Chawarski; Patricia H Owens; Linda C Degutis; Susan H Busch; Steven L Bernstein; Patrick G O'Connor Journal: Ann Emerg Med Date: 2012-03-28 Impact factor: 5.721
Authors: Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin Journal: JAMA Date: 2015-04-28 Impact factor: 56.272
Authors: Herbert C Duber; Isabel A Barata; Eric Cioè-Peña; Stephen Y Liang; Eric Ketcham; Wendy Macias-Konstantopoulos; Shawn A Ryan; Mark Stavros; Lauren K Whiteside Journal: Ann Emerg Med Date: 2018-06-05 Impact factor: 5.721
Authors: Edouard Coupet; Gail D'Onofrio; Marek Chawarski; E J Edelman; Patrick G O'Connor; Patricia Owens; Shara Martel; David A Fiellin; Ethan Cowan; Lynne Richardson; Kristen Huntley; Lauren K Whiteside; Michael S Lyons; Richard E Rothman; Michael Pantalon; Kathryn Hawk Journal: Drug Alcohol Depend Date: 2020-11-26 Impact factor: 4.492
Authors: Susan L Calcaterra; Ingrid A Binswanger; E Jennifer Edelman; Bryan K McNair; Sarah E Wakeman; Patrick G O'Connor Journal: Subst Abus Date: 2020-04-08 Impact factor: 3.716
Authors: Dennis P Watson; Tess Weathers; Alan McGuire; Alex Cohen; Philip Huynh; Clay Bowes; Daniel O'Donnell; Krista Brucker; Sumedha Gupta Journal: Drug Alcohol Depend Date: 2021-02-15 Impact factor: 4.492
Authors: Gillian A Beauchamp; Lexis T Laubach; Samantha B Esposito; Ali Yazdanyar; Paige Roth; Priyanka Lauber; Jamie Allen; Nathan Boateng; Samantha Shaak; David B Burmeister Journal: J Med Toxicol Date: 2020-11-04